12:00 AM
 | 
Jun 09, 2014
 |  BC Week In Review  |  Company News  |  Deals

Oncoceutics Inc., Sorrento Therapeutics Inc., The Scripps Research Institute deal

Scripps exclusively licensed to Sorrento a patent covering the correct chemical structure for Oncoceutics' ONC201. Scripps received an undisclosed upfront payment and will be eligible for milestones and royalties. ONC201 was originally discovered by Boehringer Ingelheim GmbH (Ingelheim, Germany) and distributed by NIH's NCI. Researchers at the Penn State Milton S. Hershey Medical Center identified its antitumor effects in mouse models and exclusively licensed...

Read the full 317 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >